Table 3 Adverse events of any cause experienced by ≥10 % patients over the study (N = 19)

Aphthous stomatitis

11 (57.9)

11 (57.9)

0 (0.0)

0 (0.0)

Hypercholesterolaemia

11 (57.9)

5 (26.3)

6 (31.6)

0 (0.0)

Hypertriglyceridaemia

8 (42.1)

3 (15.8)

3 (15.8)

2 (10.5)

Urinary tract infection

8 (42.1)

2 (10.5)

6 (31.6)

0 (0.0)

Mucosal inflammation

7 (36.8)

5 (26.3)

1 (5.3)

1 (5.3)

Hypertension

6 (31.6)

3 (15.8)

2 (10.5)

1 (5.3)

Dermatitis acneiform

5 (26.3)

5 (26.3)

0 (0.0)

0 (0.0)

Insomnia

5 (26.3)

5 (26.3)

0 (0.0)

0 (0.0)

Catarrh

4 (21.1)

4 (21.1)

0 (0.0)

0 (0.0)

Diarrhoea

4 (21.1)

3 (15.8)

1 (5.3)

0 (0.0)

Amenorrhoea

3 (15.8)

3 (15.8)

0 (0.0)

0 (0.0)

Asthenia

3 (15.8)

3 (15.8)

0 (0.0)

0 (0.0)

Headache

3 (15.8)

3 (15.8)

0 (0.0)

0 (0.0)

Dysgeusia

3 (15.8)

3 (15.8)

0 (0.0)

0 (0.0)

Pharyngitis

3 (15.8)

3 (15.8)

0 (0.0)

0 (0.0)

Nasopharyngitis

3 (15.8)

2 (10.5)

1 (5.3)

0 (0.0)

Cough

3 (15.8)

3 (15.8)

0 (0.0)

0 (0.0)

Menstrual disorder

3 (15.8)

3 (15.8)

0 (0.0)

0 (0.0)

Conjunctivitis

2 (10.5)

2 (10.5)

0 (0.0)

0 (0.0)

Dermatitis

2 (10.5)

2 (10.5)

0 (0.0)

0 (0.0)

Back pain

2 (10.5)

2 (10.5)

0 (0.0)

0 (0.0)

Abdominal pain upper

2 (10.5)

2 (10.5)

0 (0.0)

0 (0.0)

Epistaxis

2 (10.5)

2 (10.5)

0 (0.0)

0 (0.0)

Erythema

2 (10.5)

1 (5.3)

1 (5.3)

0 (0.0)

Rash

2 (10.5)

2 (10.5)

0 (0.0)

0 (0.0)

Oral herpes

2 (10.5)

2 (10.5)

0 (0.0)

0 (0.0)

Dizziness

2 (10.5)

2 (10.5)

0 (0.0)

0 (0.0)

Menorrhagia

2 (10.5)

2 (10.5)

0 (0.0)

0 (0.0)

Myalgia

2 (10.5)

2 (10.5)

0 (0.0)

0 (0.0)

Pyrexia

2 (10.5)

2 (10.5)

0 (0.0)

0 (0.0)

Vomiting

2 (10.5)

2 (10.5)

0 (0.0)

0 (0.0)

Gamma-glutamyltransferase increased

2 (10.5)

0 (0.0)

2 (10.5)

0 (0.0)

Transaminases increased

2 (10.5)

0 (0.0)

1 (5.3)

1 (5.3)